簡(jiǎn)介:TD139是吸入式的半乳凝素-3 (galectin-3) 抑制劑,Kd 值為14 nM。
TD139物理化學(xué)性質(zhì):
密度 |
1.8±0.1 g/cm3 |
沸點(diǎn) |
1017.2±75.0 °C at 760 mmHg |
分子式 |
C28H30F2N6O8S |
分子量 |
648.635 |
閃點(diǎn) |
569.0±37.1 °C |
精確質(zhì)量 |
648.181396 |
LogP |
2.19 |
蒸汽壓 |
0.0±0.3 mmHg at 25°C |
折射率 |
1.761 |
TD139詳細(xì)介紹:
中文名稱(chēng): |
TD139 |
中文別名: |
(2R,2'R,3R,3'R,4S,4'S,5R,5'R,6S,6'S)-6,6'-硫代雙(4-(4-(3-氟苯基)-1H-1,-1H-1,2,3-三唑-1-基)-2-(羥甲基)四氫-2H-吡喃-3,5-二醇) |
英文名稱(chēng): |
3-Deoxy-3-[4-(3-Fluorophenyl)-1h-1,2,3-Triazol-1-Yl]-beta-D-Galactopyranosyl 3-Deoxy-3-[4-(3-Fluorophenyl)-1h-1,2,3-Triazol-1-Yl]-1-Thio-beta-D-Galactopyranoside |
英文別名: |
TD139;TD-139;TD 139;60Y0GUO72B;(2R,2'R,3R,3'R,4S,4'S,5R,5'R,6S,6'S)-6,6'-Thiobis(4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol);3-Deoxy-3-[4-(3-Fluorophenyl)-1h-1,2,3-Triazol-1-Yl]-Beta-D-Galactopyranosyl 3-Deoxy-3-[4-(3-Fluorophenyl)-1h-1,2,3-Triazol-1-Yl]-1-Thio-Beta-D-Galactopyranoside;TD2;DB12895;beta-D-Galactopyranoside, 3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2, |
CAS號(hào): |
1450824-22-2 |
分子式: |
C28H30F2N6O8S |
分子量: |
648.64 |
詳細(xì)描述: |
博飛美科提供1450824-22-2,TD139,Perfemiker,上?,F(xiàn)貨。 Medlife,致力于提供高品質(zhì)、高性價(jià)比小分子化合物的產(chǎn)品。 Medlife小分子化合物大量庫(kù)存,提供超過(guò)2萬(wàn)種的抑制劑、激動(dòng)劑、拮抗劑等產(chǎn)品,是藥物及疾病研究的重要原料供應(yīng)商。 TD139是吸入式的半乳凝素-3 (galectin-3) 抑制劑,Kd 值為14 nM。 查詢關(guān)鍵詞:“1450824-22-2,TD139,PC16982,Perfemiker,上?,F(xiàn)貨”。 |
TD139參考文獻(xiàn):
[1]. Mackinnon AC, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012 Mar 1;185(5):537-46.
[2]. Volarevic V, et al. Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice. Hepatology. 2012 Jun;55(6):1954-64.